Literature DB >> 10338263

Micronized progesterone: a new therapeutic option.

R D Langer1.   

Abstract

The recent release of micronized progesterone adds a new physiologic alternative to the available therapeutic agents for common indications in both pre- and postmenopausal women. This compound overcomes problems with absorption through the gut associated with exogenous progesterone administration so that it can be used orally to achieve required serum and tissue levels of a hormone that is structurally identical to endogenous progesterone. Available data suggest that it is functionally equivalent to synthetic progestogens for common applications, such as secondary amenorrhea, while offering the advantage of a more physiologic metabolic profile that could be important for sustained use in applications such as postmenopausal hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338263

Source DB:  PubMed          Journal:  Int J Fertil Womens Med        ISSN: 1534-892X


  1 in total

1.  The GABAA antagonist bicuculline attenuates progesterone-induced memory impairments in middle-aged ovariectomized rats.

Authors:  B Blair Braden; Melissa L Kingston; Elizabeth N Koenig; Courtney N Lavery; Candy W S Tsang; Heather A Bimonte-Nelson
Journal:  Front Aging Neurosci       Date:  2015-08-14       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.